Common questions about Kevzara (FAQ)
Q: How soon after starting Kevzara do people typically feel effects?
A: Studies indicate that changes related to Kevzara begin relatively quickly. Official clinical trial summaries show a rapid reduction in C-reactive protein (CRP), a lab marker of inflammation, with observed improvements in physical function and symptom reduction often starting within weeks of starting treatment.
Q: Can Kevzara affect liver function test results?
A: Yes, regulatory documents indicate that treatment with Kevzara is associated with increases in liver transaminases (ALT and AST). Because of this, monitoring of these liver enzyme levels is required both before initiating therapy and at defined intervals throughout treatment.
Q: Does Kevzara affect cholesterol levels?
A: Official information states that Kevzara treatment has been associated with increases in certain lipid parameters, including LDL, HDL cholesterol, and triglycerides. For this reason, official product information indicates that lipid levels are assessed at the start of therapy and periodically thereafter.
Q: Can Kevzara be taken if you have had hepatitis B or C in the past?
A: The drug is generally avoided in patients with active infections, and the potential for a viral flare-up (reactivation) is a recognized consideration for people who have a past history of hepatitis. Regulatory documents specify that a patient's hepatitis status is evaluated by a healthcare provider before initiating Kevzara.
Q: What if I get pregnant while using Kevzara?
A: Official guidance on use during pregnancy states that Kevzara is generally recommended only if the potential benefit to the mother is considered to justify the potential risk to the fetus. The drug's official information notes the potential for harm to an unborn baby.
Q: How is Kevzara different from Humira, generally speaking?
A: Kevzara is officially classified as an Interleukin-6 (IL-6) receptor antagonist, meaning it works by specifically blocking the IL-6 inflammatory signaling pathway. Other classes of biologic drugs, such as Humira, operate by targeting a different molecule, such as Tumor Necrosis Factor (TNF).
Q: Can Kevzara be stopped suddenly, or does it need to be tapered?
A: Official documents do not describe a standard tapering process for stopping the drug. Instead, regulatory documents indicate the drug is discontinued if laboratory values fall below certain safety thresholds or if a serious infection develops.
Q: What happens if you miss a dose of Kevzara?
A: Regulatory guidance provides specific instructions for missed doses. If a dose is missed by three days or less, official guidance describes that the administration can typically be given immediately, and the schedule is then reset. If it has been four days or more, the guidance indicates that the administration occurs at the next regularly scheduled time, and doubling the dose is not advised.
Q: Is it common to have an injection site reaction with Kevzara?
A: Yes, injection site reactions are listed among the common adverse reactions in official safety profiles. These reactions typically include reddening (erythema) at the injection site, affecting a noticeable portion of adults in clinical trials.
Q: Is Kevzara safe to use long-term?
A: Clinical studies supporting the drug's approval included long-term extension phases that continued to monitor patient safety for up to several years. These extensions continued to observe the safety profile, and official information did not report new safety findings unique to these extended periods of observation.
Q: Does Kevzara interact with common cold or flu medications?
A: Kevzara may change the activity of certain liver enzymes, known as CYP P450, which are responsible for metabolizing many other medicines, including some used for cold and flu symptoms. This potential effect means that monitoring may be necessary when Kevzara is used with drugs that have a narrow therapeutic index.
Q: Is there a possibility of developing cancer while using Kevzara?
A: The mechanism of action of drugs that affect the immune system, including Kevzara, may increase the risk of certain cancers. The potential for an increased risk of certain cancers is generally acknowledged within the regulatory labeling for this class of medicine.
Q: Does Kevzara interact with birth control pills?
A: Yes, regulatory documents note that Kevzara may affect the concentration and activity of certain medicines metabolized by liver enzymes (CYP3A4), which includes oral contraceptives (birth control pills). The official information suggests that monitoring may be necessary due to this potential interaction.
Q: How long does Kevzara stay in your system after stopping treatment?
A: Pharmacokinetic data shows that the half-life of sarilumab is approximately 8 to 11 days. Given that a drug is typically eliminated after about five half-lives, the drug and its effects on certain laboratory markers may persist for over a month following the last administered dose.
Q: Is Kevzara approved for use in children?
A: Kevzara has a specific approval for the treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA). This pediatric use is established for patients aged 2 years and older who weigh 63 kg or greater.
Q: Can Kevzara be taken if I am planning a surgery?
A: Because the drug is associated with an increased risk of serious infection, which is a major consideration around surgery, regulatory documents indicate that the healthcare provider is to be informed if a patient is planning to have any surgery or medical procedure.
Q: Is fatigue a common experience when starting Kevzara?
A: Fatigue is listed as a common adverse reaction in the clinical trial data for polymyalgia rheumatica (PMR) patients treated with Kevzara, meaning it occurred in a noticeable percentage of the study population.
Q: Do all people using Kevzara get side effects?
A: Regulatory data presents side effects as incidence rates (e.g., how many people in a study of 100 or 1,000 experienced it). This format indicates that the potential for any specific side effect to occur is variable among individuals.
Q: Is Kevzara used for psoriatic arthritis?
A: The official regulatory indications for Kevzara include rheumatoid arthritis (RA), polymyalgia rheumatica (PMR), and polyarticular juvenile idiopathic arthritis (pJIA). The official labeling does not currently include psoriatic arthritis.
Q: What should be done if a new infection starts while on Kevzara?
A: Official guidance advises that treatment with Kevzara should be temporarily withheld in patients who develop a serious infection. The product information states that treatment is typically not resumed until the infection is controlled.
Q: Are there any known issues with Kevzara and dental work?
A: Official documents indicate that patients are to inform their healthcare provider if they are planning a medical procedure. This includes procedures like significant dental work, which may carry a risk of infection that could be a concern while taking an immunosuppressive medicine.
Q: Can Kevzara be used for conditions other than rheumatoid arthritis?
A: Yes, Kevzara is also officially indicated and approved for the treatment of polymyalgia rheumatica (PMR) and polyarticular juvenile idiopathic arthritis (pJIA) in specific, defined patient populations.
Q: Can Kevzara make you feel dizzy or lightheaded?
A: Dizziness or feeling faint is listed in patient information as a symptom that requires immediate attention, as it may be a sign of a serious allergic reaction to the drug.
